title: The hepatitis C genotype 1 paradox: cost per treatment is increasing, but cost per cure is decreasing.
abstract: Significant attention has been focused on the perceived increase in the cost of antiviral treatment for hepatitis C genotype 1 infection since the approval of the first direct-acting antiviral agents in 2011. Using Canadian list prices, the present analysis points out a paradox: while the cost per antiviral regimen is increasing, the cost per cure is decreasing, especially with interferon-free therapy. In a publicly funded health care system, the lowest cost per cure is a more valuable measure of value for public money than the cost per regimen.
authors.forename: Stephen D
authors.initials: SD
authors.lastname: Shafran
mesh_terms: D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use; D002170:Canada; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000191:economics*; D006801:Humans
chemical_list: D000998:Antiviral Agents